Positive Phase III results for Eisai's Zebinix in elderly patients

26 May 2015

Data for once-daily, anti-epileptic drug Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai (TYO: 4523) shows it to be effective and well tolerated in elderly people with partial onset seizures (POS), with a 54% decrease in seizure frequency from baseline observed over the maintenance period of the study.

These data were presented in full at the Association of British Neurologists Annual Meeting in Harrogate, UK, May 20-22, 2015.

Old age is the most common time to develop epilepsy and treatment of this age group remains a challenge due to the high presence of co-morbidities and the need for polypharmacy. Seizure control and reduction of side effects are key treatment goals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK